Skip to content

Biomarker improvement and development in non-endoscopic samples

Biomarker improvement and development in non-endoscopic samples within the Cyted diagnostic pathway

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN15151491
Enrollment
10000
Registered
2023-01-31
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosis of oesophageal conditions in patients with reflux including Barrett's oesophagus, Oesophageal cancer, and Eosinophilic oesophagitis. Digestive System

Interventions

This study is a single-centre retrospective cohort study using diagnostic samples collected during a routine diagnostic procedure and reported a minimum of 3 months prior to inclusion.

Sponsors

Cyted Ltd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient aged 18 and over 2. Male or female 3. Final pathology report submitted a minimum of 3 months prior to search

Exclusion criteria

Exclusion criteria: 1. Samples submitted less than 3 months prior search 2. Samples that have not yet resulted in a pathology report

Design outcomes

Primary

MeasureTime frame
1. Sensitivity/specificity for any new biomarker for the given endpoint (1) diagnosis of Barrett's by endoscopy OR (2) risk of cancer) at the end of the study 2. Accuracy as measured against the pathologist's diagnosis for Barrett's diagnosis at the end of the study

Secondary

MeasureTime frame
1. General improvements to our internal laboratory processes for sample testing and reporting to pathologists. Improvements are measured against the current internal standard for sample processing. Each improvement will be evaluated against an appropriate internal sample set, sample size calculations will be performed based on the specific process we address. The final timepoint for all improvement studies will be the end of the study. 2. Identification of biomarkers for other oesophageal conditions including EoE or OSCC measured using a combination of IHC biomarkers, the gold standard for any new biomarker is our pathologist's diagnosis and non-inferiority with our current IHC biomarker tests. Timepoint is at the end of the study.

Countries

England, United Kingdom

Contacts

Public ContactBasirat Afinowi
basirat.afinowi@cyted.ai+44 (0)1480 453 437

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026